8 May 2019 - Novartis is confident it has adequate production capacity for its Zolgensma gene therapy should regulators this month approve the drug for multiple forms of the genetic disease spinal muscular atrophy, the Swiss drug maker said on Wednesday.

Basel-based Novartis has several clinical trials ongoing, including against spinal muscular atrophy Type 1, which often kills infants before the age of two, as well as spinal muscular atrophy Type 2, a slower-moving but still disabling form of the inherited disease where victims lack functioning copies of a gene needed for motor neuron development.

The U.S. Food and Drug Administration is expected to make a decision on the gene therapy by 31 May.

Read Reuters article